A Phase 1b, Single Center, Clinical Study to Investigate the Safety and Biological Responses to Baminercept in Patients With Chronic HCV Hepatitis.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Baminercept (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 28 Jul 2010 New trial record
- 16 Jul 2010 Biomarkers information updated